![\"vaccine](\"https:\/\/i0.wp.com\/www.malaysiaworldnews.com\/wp-content\/uploads\/2021\/05\/vaccine-false.jpg?resize=1111%2C444&ssl=1\" "\\"57")
<\/div>\n<\/div>\nA group of 57 leading scientists, doctors and political experts have released a report questioning the safety and efficacy of current COVID-19 \u201d vaccines \u201c, and are now calling for an immediate stop to all vaccination programs, A French blog FranceSoir reported.<\/p>\n
Among 57 scientists is the geneticist Alexandra Henrion-Caude, from French Institute of Health and Medical Research | Inserm \u00b7 Unit of Genetics and Epigenetics of Neurometabolic Diseases and Birth Defects
\nDirector of Research, Inserm, the report said.<\/p>\n
The \u201cvaccines\u201d, they said, do not meet the definition of the word vaccine and it would be more appropriate to call them \u201cgene therapy\u201d or \u201cvaccine vector therapy .\u201d<\/p>\n
There are two certainties regarding the global distribution of these Covid-19 therapies:<\/p>\n
The first is that governments and the vast majority of mainstream media are working hard to make these investigational drugs available to as many people as possible.<\/p>\n
The second is that those who are prepared to face the contempt that comes with asking serious questions about vaccines are essential players in our ongoing efforts to spread the truth.<\/p>\n
The group of scientists have also release pre-print manuscript on the net and asking people to read it.<\/p>\n
The manuscript has been prepared by nearly sixty doctors, scientists and public policy experts around the world to be sent urgently to world leaders, as well as to all those associated with the production and distribution of the various Covid-19 vaccines.<\/p>\n
There are still far too many unanswered questions regarding the safety , efficacy and necessity of these Covid-19 therapies, they claim, adding that there are not enough citizens asking questions. Most people just follow the orders of world governments, as if they\u2019ve earned our full trust.<\/p>\n
Read the manuscript here:\u00a0https:\/\/www.francesoir.fr\/societe-sante\/57-scientifiques-et-medecins-demandent-larret-immediat-de-toutes-les-vaccinations#.YJjg6cXUI0p.whatsapp<\/a><\/p>\n Below is the translation of this French manuscript:<\/p>\n Mass vaccination against SARS-CoV-2: urgent vaccine safety questions that demand answers from international health agencies, regulatory authorities, governments and vaccine developers<\/strong><\/p>\n Authors: Roxana Bruno (1), Peter McCullough (2), Teresa Forcades i Vila (3), Alexandra Henrion-Caude (4), Teresa Garc\u00eda-Gasca (5), Galina P. Zaitzeva (6), Sally Priester (7 ), Mar\u00eda J. Mart\u00ednez Albarrac\u00edn (8), Alejandro Sousa-Escandon (9), Fernando L\u00f3pez Mirones (10), Bartomeu Payeras Cifre (11), Almudena Zaragoza Velilla (10), Leopoldo M. Borini () 1, Mario Mas (1), Ramiro Salazar (1), Edgardo Schinder (1), Eduardo A Yahbes (1), Marcela Witt (1), Mariana Salmeron (1), Patricia Fern\u00e1ndez (1), Miriam M. Marchesini (1), Alberto J. Kajihara (1), Marisol V. de la Riva (1), Patricia J. Chimeno (1), Paola A. Grellet (1), Matelda Lisdero (1), Pamela Mas (1), Abelardo J. Gatica Baudo (12), Elisabeth Retamoza (12), Oscar Botta (13), Chinda C. Brandolino (13), Javier Sciuto (14), Mario Cabrera Avivar (14),Mauricio Castillo (15), Patricio Villarroel (15), Emilia P. Poblete Rojas (15), B\u00e1rbara Aguayo (15), Dan I. Mac\u00edas Flores (15), Jose V. Rossell (16), Julio C. Sarmiento (17 ), Victor Andrade-Sotomayor (17), Wilfredo R. Stokes Baltazar (18), Virna Cede\u00f1o Escobar (19), Ulises Arr\u00faa (20), Atilio Farina del R\u00edo (21), Tatiana Campos Esquivel (22), Patricia Callisperis ( 23), Mar\u00eda Eugenia Barrientos (24), Karina Acevedo-Whitehouse (5),Karina Acevedo-Whitehouse (5),Karina Acevedo-Whitehouse (5),<\/p>\n Summary<\/strong><\/p>\n Since the start of the COVID-19 epidemic, the race to test new platforms designed to confer immunity against SARS-CoV-2 has been rampant and unprecedented, leading to the emergency clearance of various vaccines.\u00a0Despite advances in early multidrug therapy for patients with COVID-19, the current mandate is to immunize the world\u2019s population as quickly as possible.\u00a0The lack of extensive animal testing before clinical trials, and the authorization based on safety data generated in trials that lasted less than 3.5 months, raise questions about the safety of these vaccines.\u00a0The recently identified role of the SARS-CoV-2 glycoprotein spike which can induce endothelial damage characteristic of COVID-19, even in the absence of infection,\u00a0is extremely relevant given that most licensed vaccines induce the production of Spike glycoprotein in recipients.\u00a0Given the high rate of occurrence of adverse reactions and the wide range of types of adverse reactions reported to date, as well as the potential for improvement in vaccine disease, Th2 immunopathology, auto -immunity and immune evasion, there is the need for a better understanding of the benefits and risks of mass vaccination, especially in groups excluded from clinical trials.\u00a0Despite calls for caution, the risks of SARS-CoV-2 vaccination have been downplayed or ignored by health organizations and government authorities.\u00a0Given the high rate of occurrence of adverse reactions and the wide range of types of adverse reactions reported to date, as well as the potential for improvement in vaccine disease, Th2 immunopathology, auto -immunity and immune evasion, there is the need for a better understanding of the benefits and risks of mass vaccination, especially in groups excluded from clinical trials.\u00a0Despite calls for caution, the risks of SARS-CoV-2 vaccination have been downplayed or ignored by health organizations and government authorities.\u00a0Given the high rate of occurrence of adverse reactions and the wide range of types of adverse reactions reported to date, as well as the potential for improvement in vaccine disease, Th2 immunopathology, auto -immunity and immune evasion, there is the need for a better understanding of the benefits and risks of mass vaccination, especially in groups excluded from clinical trials.\u00a0Despite calls for caution, the risks of SARS-CoV-2 vaccination have been downplayed or ignored by health organizations and government authorities.\u00a0of Th2 immunopathology, autoimmunity and immune evasion, there is the need for a better understanding of the benefits and risks of mass vaccination, especially in groups excluded from clinical trials.\u00a0Despite calls for caution, the risks of SARS-CoV-2 vaccination have been downplayed or ignored by health organizations and government authorities.\u00a0of Th2 immunopathology, autoimmunity and immune evasion, there is the need for a better understanding of the benefits and risks of mass vaccination, especially in groups excluded from clinical trials.\u00a0Despite calls for caution, the risks of SARS-CoV-2 vaccination have been downplayed or ignored by health organizations and government authorities.\u00a0We call for the need for a pluralist dialogue within the framework of health policies.<\/strong><\/p>\n Introduction<\/strong><\/p>\n Since the declaration of the Covid-19 pandemic in March 2020, more than 150 million cases and 3 million deaths have been reported worldwide.\u00a0Despite advances in early outpatient multidrug therapy for high-risk patients, resulting in an 85% reduction in hospitalizations and deaths from COVID-19 [1],\u00a0the current paradigm of control is mass vaccination<\/strong>\u00a0.\u00a0While we recognize the effort involved in the development, production, and emergency authorization of SARS-CoV-2 vaccines, we are concerned that the risks have been minimized or ignored by healthcare organizations. and government authorities, despite cautions [2-8].<\/p>\n Vaccines against other coronaviruses have never been approved for humans, and data generated in the development of coronavirus vaccines designed to elicit neutralizing antibodies shows they may worsen COVID-19 disease via improvement dependent on antibodies (ADE) and Th2 immunopathology, regardless of the vaccine.\u00a0Platform and delivery method [9-11].\u00a0The increase in vaccine-borne illness in animals vaccinated against SARS-CoV and MERS-CoV is known to occur following viral challenge and has been attributed to immune complexes and viral uptake. Fc-mediated by macrophages, which increase T cell activation and inflammation [11 -13].<\/p>\n In March 2020, vaccine immunologists and coronavirus experts assessed the risks of the SARS-CoV-2 vaccine, based on trials of SARS-CoV vaccines in animal models.\u00a0The expert group concluded that both ADR and immunopathology\u00a0are a real concern<\/strong>\u00a0, but said\u00a0their risk was insufficient<\/strong>to delay clinical trials, although continued monitoring would be necessary [14].\u00a0Although there is no clear evidence for the occurrence of ADEs and vaccine-related immunopathology in volunteers immunized with SARS-CoV-2 vaccines [15], safety trials to date no did not specifically address these serious side effects (SAEs).\u00a0Since the follow-up of the volunteers did not exceed 2-3.5 months after the second dose [16-19], it is unlikely that such an SAE was observed.\u00a0Despite 92 reporting errors, it cannot be ignored that even taking into account the number of vaccines administered, according to the American Adverse Vaccine Reaction Reporting System (VAERS), the number of deaths per million doses of vaccine administered has multiplied. by more than 10.<\/p>\n In this article, we describe some of the risks of mass vaccination in the context of exclusion criteria for phase 3 trials and discuss the SAE reported in national and regional adverse reaction recording systems.\u00a0We highlight unanswered questions and draw attention to the need for a more cautious approach to mass immunization.\u00a0We believe there is an urgent need for an open scientific dialogue on vaccine safety, in the context of large-scale immunization.\u00a0In this article, we describe some of the risks of mass vaccination in the context of exclusion criteria for phase 3 trials and discuss the SAE reported in national and regional adverse reaction recording systems.\u00a0We highlight unanswered questions and draw attention to the need for a more cautious approach to mass immunization.\u00a0We believe there is an urgent need for an open scientific dialogue on vaccine safety in the context of large-scale immunization.\u00a0In this article, we describe some of the risks of mass vaccination in the context of exclusion criteria for phase 3 trials and discuss the SAE reported in national and regional adverse reaction recording systems.\u00a0We highlight unanswered questions and draw attention to the need for a more cautious approach to mass immunization.\u00a0a more cautious approach to mass vaccination.\u00a0We believe there is an urgent need for an open scientific dialogue on vaccine safety in the context of large-scale immunization.\u00a0In this article, we describe some of the risks of mass vaccination in the context of exclusion criteria for phase 3 trials and discuss the SAE reported in national and regional adverse reaction recording systems.\u00a0We highlight unanswered questions and draw attention to the need for a more cautious approach to mass immunization.\u00a0a more cautious approach to mass vaccination.\u00a0We believe there is an urgent need for an open scientific dialogue on vaccine safety in the context of large-scale immunization.\u00a0In this article, we describe some of the risks of mass vaccination in the context of exclusion criteria for phase 3 trials and discuss the SAE reported in national and regional adverse reaction recording systems.\u00a0We highlight unanswered questions and draw attention to the need for a more cautious approach to mass immunization.\u00a0we describe some of the risks of mass vaccination in the context of exclusion criteria for phase 3 trials and discuss the SAE reported in national and regional adverse reaction recording systems.\u00a0We highlight unanswered questions and draw attention to the need for a more cautious approach to mass immunization.\u00a0we describe some of the risks of mass vaccination in the context of exclusion criteria for phase 3 trials and discuss the SAE reported in national and regional adverse reaction recording systems.\u00a0We highlight unanswered questions and draw attention to the need for a more cautious approach to mass immunization.<\/p>\n SARS-CoV-2 Phase 3 Trial Exclusion Criteria<\/strong><\/p>\n With few exceptions, SARS-CoV-2 vaccine trials excluded the elderly [16-19], making it impossible to identify the occurrence of post-vaccination eosinophilia and increased inflammation. in the elderly.\u00a0Studies with SARS-CoV vaccines have shown that elderly immunized mice are at particularly high risk of potentially fatal Th2 immunopathology [9,20].\u00a0Despite this evidence and the extremely limited data on the safety and effectiveness of SARS-CoV-2 vaccines in the elderly, mass vaccination campaigns have focused on this age group from the start.\u00a0Most trials also excluded pregnant and breastfeeding volunteers, as well as those with<\/p>\n Another exclusion criterion from almost all trials was prior exposure to SARS-CoV-2.\u00a0This is unfortunate because it removed the possibility of obtaining extremely relevant information regarding post-vaccine adverse reactions in people who already have anti-SARS-Cov-2 antibodies.\u00a0To the best of our knowledge, EADs are not routinely monitored for any age or group of medical conditions currently receiving the vaccine.\u00a0In addition, despite a substantial proportion of the population already having antibodies [21], tests to determine the status of anti-SARS-CoV-2 antibodies before vaccine administration are not performed routinely.<\/p>\n Will serious side effects from SARS-CoV-2 vaccines go unnoticed?<\/strong><\/p>\n COVID-19 encompasses a broad clinical spectrum, ranging from very mild or severe pulmonary pathology, to a fatal multi-organ disease with inflammatory, cardiovascular and even blood coagulation deregulation [22-24].\u00a0In this sense, cases of ADR or immunopathology related to the vaccine would be clinically indistinguishable from severe COVID-19 [25].\u00a0Additionally, even in the absence of SARS-CoV-2 virus, Spike\u2019s glycoprotein alone causes endothelial damage and hypertension in vitro and in vivo in Syrian hamsters by down-regulating the ACE-converting enzyme. angiotensin 2 (ACE2) and altering mitochondrial function [26].\u00a0Although these results need to be confirmed in humans, the implications of this finding are staggering.\u00a0because all vaccines authorized for emergency use are based on the administration or induction of Spike glycoprotein synthesis.\u00a0In the case of mRNA vaccines and adenovirus vector vaccines, no studies have examined the duration of Spike production in humans after vaccination.<\/p>\n According to the precautionary principle, it is parsimonious to consider that the synthesis of Spike induced by the vaccine could cause clinical signs of severe COVID-19 and be wrongly counted as new cases of infections with SARS-CoV-2.\u00a0If so, the true side effects of the current global immunization strategy may never be recognized unless studies specifically examine this issue.\u00a0There is already non-causal evidence of a temporary or sustained increase in deaths from COVID-19 following vaccination in some countries (Fig. 1).\u00a0In light of Spike\u2019s pathogenicity, these deaths should be thoroughly investigated to determine if they are related to vaccination.\u00a0No studies have examined the duration of Spike production in the<\/p>\n Unexpected Adverse Reactions to SARS-CoV-2 Vaccines<\/strong><\/p>\n Autoimmunity is another critical issue to consider given the global scale of SARS-CoV-2 vaccination.\u00a0SARS-CoV-2 has many immunogenic proteins, and all but one have similarities to human proteins [27].\u00a0These can act as a source of antigens, leading to autoimmunity [28].\u00a0While it is true that the same effects could be observed with natural infection with SARS-CoV-2, vaccination is intended for most of the world\u2019s population, while it is estimated that only 10% of the population Global population has been infected with SARS-CoV -2, according to Dr Michael Ryan, head of emergencies at the World Health Organization.\u00a0We could not find any proof that<\/p>\n Some side effects, including blood clotting disorders, have already been reported in healthy and young vaccinated people.\u00a0These cases have led to the suspension or cancellation of the use of the adenoviral vector vaccines ChAdOx1-nCov-19 and Janssen in some countries.\u00a0It has now been proposed that vaccination with ChAdOx1-nCov-19 may result in immune thrombotic thrombocytopenia (VITT) mediated by platelet-activating antibodies against platelet factor-4, which clinically mimics heparin-induced autoimmune thrombocytopenia [29].\u00a0Unfortunately, the risk was overlooked when authorizing these vaccines,\u00a0although adenovirus-induced thrombocytopenia has been known for over a decade and has been a consistent occurrence with adenoviral vectors [30].\u00a0The risk of VITT is likely to be higher in people who are already at risk for blood clots.<\/p>\n At the population level, there could also be vaccine-related impacts.\u00a0SARS-CoV-2 is a rapidly evolving RNA virus, which has so far produced more than 40,000 variants [32,33], some of which affect the antigenic domain of Spike\u2019s glycoprotein [34,35].\u00a0Given the high mutation rates, vaccine-induced synthesis of high levels of anti-SARS-CoV-2-Spike antibodies could theoretically lead to suboptimal responses against subsequent infections by other variants in individuals. vaccinated [36], a phenomenon known as \u201csin\u201d [37] or antigen priming [38].\u00a0It is not known to what extent mutations that affect SARS-CoV-2 antigenicity will bind during viral evolution [39],\u00a0but vaccines could presumably act as selective forces leading to variants with higher infectivity or transmissibility.\u00a0Given the strong similarity between known variants of SARS-CoV-2, this scenario is unlikely [32,34] but if future variants were to differ further in key epitopes, the global vaccination strategy could have helped shape an even more dangerous virus.\u00a0This risk was recently brought to the attention of WHO in the form of an open letter [40].\u00a0the global vaccination strategy could have helped shape an even more dangerous virus.\u00a0This risk was recently brought to the attention of WHO in the form of an open letter [40].\u00a0the global vaccination strategy could have helped shape an even more dangerous virus.\u00a0This risk was recently brought to the attention of WHO in the form of an open letter [40].<\/p>\n Discussion<\/strong><\/p>\n The risks described here constitute a major obstacle to the pursuit of global vaccination against SARS-CoV-2.\u00a0Evidence of the safety of all SARS-CoV-2 vaccines is needed before more people are exposed to the risk of these experiences, as the release of a candidate vaccine without the time to fully understand the impact that would result on health, could lead to an exacerbation of the current global crisis.\u00a0[41].\u00a0Risk stratification of vaccinees is essential.\u00a0According to the British government, people under the age of 60 have an extremely low risk of dying from COVID-19.\u00a0However, according to Eudravigillance, most serious side effects following SARS-CoV-2 vaccination occur in people aged 18 to 64 years.\u00a0Of particular concern is the planned vaccination schedule for children aged 6 and over in the US and UK.\u00a0Dr. Anthony Fauci recently predicted that adolescents across the country will be vaccinated in the fall and younger ones in early 2022. Lee UK is awaiting trial results to begin immunizing 11 million under children age 18 to experimental vaccines, given that the Centers for Disease Control and Prevention estimates that they have a 99.997% survival rate if they are infected with SARS-CoV-2.\u00a0Not only is COVID-19 not relevant as a threat for this age group, there is no reliable evidence to support the efficacy or effectiveness of the vaccine in this population,\u00a0or to rule out the harmful side effects of these experimental vaccines.\u00a0In this sense, when physicians advise patients for elective administration of COVID-19 vaccination, there is a great need to better understand the benefits and risks of administration, especially in poorly studied groups.<\/p>\n In conclusion, in the context of the emergency authorization of use of SARS-CoV-2 vaccines, and the current gaps in our understanding of their safety, the following questions need to be raised:<\/p>\n \u2013 Is it known whether cross-reacting antibodies from previous coronavirus infections or antibodies induced by the vaccine may influence the risk of unintentional pathogenesis after vaccination with COVID-19?<\/p>\n \u2013 Has the specific risk of ADE, immunopathology, autoimmunity and serious adverse reactions been clearly disclosed to vaccine recipients in order to meet the medical ethical standard of patient understanding for the informed consent?\u00a0If not, what are the reasons and how could it be implemented?<\/p>\n \u2013 What is the rationale for administering the vaccine to each individual when the risk of dying from COVID-19 is not equal across age groups and clinical conditions, and when phase 3 trials have excluded individuals elderly, children and frequent specific ailments?<\/p>\n \u2013 What are the legal rights of patients if they are injured by a SARS-CoV-2 vaccine?\u00a0Who will cover the cost of medical treatment?\u00a0If claims were to be settled with public funds, has the public been made aware that vaccine manufacturers have been granted immunity and that their responsibility for compensating those harmed by the vaccine has shifted to taxpayers?<\/p>\n In the context of these concerns, we propose to put an end to mass vaccination and to open an urgent pluralist, critical and scientifically-based dialogue on SARS-CoV-2 vaccination between scientists, doctors, agencies. international health organizations, regulatory authorities, governments and vaccine developers.\u00a0This is the only way to bridge the current gap between scientific evidence and public health policy regarding SARS-CoV-2 vaccines.\u00a0We are convinced that humanity deserves a deeper understanding of the risks than what is currently presented as the official position.\u00a0An open scientific dialogue is urgent and essential to avoid the\u00a0erosion of public confidence in science and public health and to ensure that WHO and national health authorities protect the interests of humanity during the current pandemic.\u00a0There is an urgent need to return public health policy to evidence-based medicine, based on careful assessment of relevant scientific research.\u00a0It is imperative to follow the science.<\/p>\n 1\u00a0\u00a0\u00a0https:\/\/www.gov.uk\/government\/publications\/covid-19-reported-sars-cov-2-deaths-in-england\/covid-19-confirmed-deaths-in-england-report<\/a><\/p>\n Declaration of conflict of interest<\/strong><\/p>\n The authors state that the research was conducted in the absence of any business or financial relationship that could be interpreted as a potential conflict of interest.<\/p>\n The references<\/strong><\/p>\n McCullough PA, Alexander PE, Armstrong R et al.\u00a0Highly targeted multifaceted sequential multidrug therapy for high-risk early ambulatory infection with SARS-CoV-2 (COVID-19).\u00a0Rev Cardiovasc Med (2020) 21: 517-530.\u00a0doi: 10.31083 \/ j.rcm.2020.04.264<\/p>\n Arvin AM, Fink K, Schmid MA, et al.\u00a0A perspective on the antibody-dependent enhancement of SARS-CoV-2.\u00a0Nature (2020) 484: 353\u2013363.\u00a0doi: 10.1038 \/ s41586-020-2538-8<\/p>\n Coish JM, MacNeil AJ.\u00a0Out of the pan and into the fire?\u00a0ADE\u2019s Due Diligence in COVID-19.\u00a0Infected Microbes (2020) 22 (9): 405-406.\u00a0doi: 10.1016 \/ j.micinf.2020.06.006<\/p>\n Eroshenko N, Gill T, Keaveney ML et al.\u00a0Implications of increased antibody-dependent infection for SARS-CoV-2 countermeasures.\u00a0Nature Biotechnol (2020) 38: 788\u2013797.\u00a0doi: 10.1038 \/ s41587-020-0577-1<\/p>\n Poland GA.\u00a0Turtles, hares and vaccines: a warning for the development of a vaccine against SARS-CoV-2.\u00a0Vaccine (2020) 38: 4219\u20134220.\u00a0doi: 10.1016 \/ j.vaccine.2020.04.073<\/p>\n Shibo J. Don\u2019t rush to deploy COVID-19 vaccines and drugs without sufficient security guarantees.\u00a0Nature (2000) 579 321. doi: 10.1038 \/ d41586-020-00751-9<\/p>\n Munoz FA, Cramer JP, Dekker CL et al.\u00a0Enhanced vaccine-associated disease: case definition and guidelines for data collection, analysis and presentation of immunization safety data.\u00a0Vaccine (2021)\u00a0\u00a0https: \/\/ doi.\u00a0org \/ 10.\u00a01016 \/ d.\u00a0vaccine.\u00a02021.\u00a001.\u00a0055<\/a><\/p>\n Cardozo T, Veazey R. Disclosure of Informed Consent to Vaccine Trial Subjects at Risk of Worsening Clinical Disease from COVID-19 Vaccines.\u00a0Int J Clin Pract (2020) 28: e13795.\u00a0doi: 10.1111 \/ ijcp.13795<\/p>\n Bolles D, Long K, Adnihothram S et al.\u00a0A double inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces an increased eosinophilic pro-inflammatory pulmonary response upon challenge.\u00a0J Virol (2001) 85: 12201-12215.\u00a0doi: 10.1128 \/ JVI.06048-11<\/p>\n Weingartl H, Czub M, Czub S, et al.\u00a0Vaccination with modified vaccinia virus Recombinant Ankarab vaccine against severe acute respiratory syndrome is associated with increased hepatitis in ferrets.\u00a0J Virol (2004) 78: 12672-12676.\u00a0doi: 10.1128 \/ JVI.78.22.12672-12676.2004272<\/p>\n Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al.\u00a0Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology when challenged with SARS virus.\u00a0PLoS One (2012) 7 (4): e35421.\u00a0doi: 10.1371 \/ journal.pone.0035421<\/p>\n Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19.\u00a0Nat Rev Immunol (2020) 20: 339\u2013341.\u00a0doi: 10.1038 \/ s41577-020-0321-6<\/p>\n Vennema H, de Groot RJ, Harbor DA, et al.\u00a0Early death after challenge with feline infectious peritonitis virus due to immunization with recombinant vaccinia virus.\u00a0J Virol (1990) 64: 1407-1409<\/p>\n Lambert PH, Ambrosino DM, Andersen SR, et al.\u00a0Consensus Summary Report for CEPI \/ BC Meeting March 12-13, 2020: Evaluating the Risk of Disease Improvement with COVID-19 Vaccines.\u00a0Vaccine (2020) 38 (31): 4783-4791.\u00a0doi: 10.1016 \/ j.vaccine.2020.05.064<\/p>\n by Alwis R, Chen S, Gan S et al.\u00a0Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.\u00a0EbioMedicine (2020) 55: 102768. doi: 10.1016 \/ j.ebiom.2020.102768<\/p>\n Folegatti PM, Ewer KJ, Aley PK, et al.\u00a0Safety and immunogenicity of ChAdOx1 nCoV vaccine?\u00a0287 19 against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomized controlled trial.\u00a0Lancet (2020) 396: 467\u2013783.\u00a0doi: 10.1016 \/ S0140-6736 (20) 31604-4<\/p>\n Polack FP, Thomas SJ, Kitchin N. Safety and efficacy of BNT162b2 mRNA Covid-19 vaccine.\u00a0N Engl J Med (2020) 383: 2603-2615.\u00a0doi: 10.1056 \/ NEJMoa2034577<\/p>\n Ramasamy MN, Minassian AM, Ewer KJ et al.\u00a0Safety and Immunogenicity of ChAdOx1 nCoV-19 Vaccine Administered as a First Aid Regimen in Young and Old Adults (COV002): A Phase 2\/3 Randomized, Single-Blind Controlled Trial Lancet (2021) 396: 1979\u201393 .\u00a0doi: 10.1016 \/ S0140-6736 (20) 32466-1<\/p>\n Chu L, McPhee R, Huang W et al.\u00a0MRNA-1273 Study Group.\u00a0A preliminary report of a phase 2 randomized controlled trial on the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.\u00a0Vaccine (2021) S0264-410X (21) 00153-5.\u00a0doi: 10.1016 \/ j.vaccine.2021.02.007<\/p>\n Liu L, Wei Q, Lin Q et al.\u00a0Anti-peak IgGs cause severe acute lung damage by skewing macrophage responses during acute SARS-CoV infection.\u00a0JCI Insight (2019) 4 (4): e123158.\u00a0doi: 10.1172 \/ jci.insight.123158.<\/p>\n Ioannidis PA.\u00a0Death rate from COVID-19 infection inferred from seroprevalence data.\u00a0Bull WHO (2021) 99: 19\u201333E.\u00a0http: \/\/ dx.\u00a0doi.\u00a0org \/ 10.\u00a02471 \/ BLT.\u00a020.\u00a0265892<\/a><\/p>\n Martines RB, Ritter JM, Matkovic E et al.\u00a0Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States Emerg Infect Dis (2020) 26: 2005-2015.\u00a0doi: 10.3201 \/ eid2609.202095<\/p>\n Wu Z, McGoogan JM.\u00a0Important features and lessons of the 2019 coronavirus disease (COVID-19) outbreak in China: summary of a report of 72,314 cases from the China Center for Disease Control and Prevention.\u00a0JAMA (2020) 323: 1239-1242.\u00a0doi: 10.1001 \/ jama.2020.2648<\/p>\n Xu Z, Shi L, Wang Y et al.\u00a0Pathological findings of COVID-19 associated with acute respiratory distress syndrome.\u00a0Lancet Respiratory Med (2020) 8: 420-422 doi: 10.1016 \/ S2213-2600 (20) 30076-X<\/p>\n Negro F. Does antibody-dependent enhancement play a role in the pathogenesis of COVID-19?\u00a0Swiss Medical Weekly (2020) 150: w20249.\u00a0doi: 10.4414 \/ smw.2020.20249317<\/p>\n Lei Y, Zhang J, Schiavon CR et al., Spike Protein Empairs Endothelial Function via Downregulation of ACE 2. Circulation Res (2021) 128: 1323\u20131326.\u00a0https: \/\/ doi.\u00a0org \/ 10.\u00a01161 \/ CIRCRESAHA.\u00a0121.\u00a0318902<\/a><\/p>\n Lyons-Weiler J. Pathogen priming likely contributes to severe and critical illness and mortality from COVID-19 via autoimmunity, J Translational Autoimmunity (2020) 3: 100051. doi: 10.1016 \/ j.jtauto. 2020.100051<\/p>\n An H, Park J. Molecular Mimicry Map (3M) of SARS-CoV-2: Prediction of potentially immunopathogenic SARS-CoV-2 epitopes via a novel immunoinformatics approach.\u00a0bioRxiv [Preprint].\u00a0November 12, 2020 [cited April 19, 2020]\u00a0\u00a0https: \/\/ doi.\u00a0org \/ 10.\u00a01101\/2020.\u00a011.\u00a012.\u00a0344424<\/a><\/p>\n Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.\u00a0N Engl J Med (2021).\u00a0doi: 10.1056 \/ NEJMoa2104840<\/p>\n Othman M, Labelle A, Mazzetti I et al.\u00a0Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.\u00a0Blood (2007) 109: 2832-2839.\u00a0doi: 10.1182 \/ sang-2006-06-032524<\/p>\n Ortel TL.\u00a0Thrombotic risk factors acquired in intensive care.\u00a0Crit Care Med (2010) 38 (2 Suppl): S43-50.\u00a0doi: 10.1097 \/ CCM.0b013e3181c9ccc8<\/p>\n Grubaugh ND, Petrone ME, Holmes EC.\u00a0We don\u2019t have to worry when a virus mutates during epidemics.\u00a0Nat Microbiol (2020) 5: 529-530.\u00a0https: \/\/ doi.\u00a0org \/ 10.\u00a01038 \/ s 41 564 \u2013 020 \u2013 0690 \u2013 4<\/a><\/p>\n Greaney AJ, Starr TN, Gilchuk P et al.\u00a0Comprehensive mapping of mutations to the SARS-CoV peak receptor binding domain?\u00a0339 2 which escape recognition of antibodies.\u00a0Cell Host Microbe (2021) 29: 44\u201357.e9.\u00a0doi: 10.1016 \/ j.chom.2020.11.007.<\/p>\n Lauring AS, Hodcroft EB.\u00a0Genetic Variants of SARS-CoV-2 \u2013 What Do They Mean?\u00a0JAMA (2021) 325: 529-531.\u00a0doi: 10.1001 \/ jama.2020.27124<\/p>\n Zhang L, Jackson CB, Mou H et al.\u00a0The D614G mutation in the SARS-CoV-2 spike protein reduces S1 excretion and increases infectivity.\u00a0bioRxiv [Preprint].\u00a0June 12, 2020 [cited April 19, 2021]\u00a0\u00a0https: \/\/ doi.\u00a0org \/ 10.\u00a01101\/2020.\u00a006.\u00a012.\u00a0148726<\/a><\/p>\n Korber B, Fischer WM, Gnanakaran S et al.\u00a0Sheffield COVID-19 Genomics Group.\u00a0Monitoring changes in SARS-CoV-2 peak: evidence that D614G increases the infectivity of the COVID-19 virus.\u00a0Cell (2020) 182: 812-827.e19.\u00a0doi: 10.1016 \/ j.cell.2020.06.043<\/p>\n Francis T. On the doctrine of original antigenic sin.\u00a0Proc Am Philos Soc (1960) 104: 572-578.<\/p>\n Vibroud C, Epstein SL.\u00a0The first flu is forever.\u00a0Science (2016) 354: 706\u2013707.\u00a0doi: 10.1126 \/ science.aak9816<\/p>\n Weisblum Y, Schmidt F, Zhang F et al.\u00a0Escape neutralizing antibodies by spike CoV-2 protein variants of SARS?\u00a0354. Elife (2020) 9: e61312.\u00a0doi: 10.7554 \/ eLife.61312<\/p>\n Vanden Bossche G (March 6, 2021)\u00a0\u00a0https: \/\/ dryburgh.\u00a0com \/ wp \u2013 356content \/ uploads \/ 2021\/03 \/ Geert _ Vanden _ Bossche _ Open _ Letter _ WHO _ March _ 6 _ 2021.\u00a0pdf<\/a><\/p>\n Coish JM, MacNeil AJ.\u00a0Out of the pan and into the fire?\u00a0ADE\u2019s Due Diligence in COVID-19.\u00a0Infected Microbes (2020) 22 (9): 405-406.\u00a0doi: 10.1016 \/ j.micinf.2020.06.006<\/p>\n Figure captions<\/p>\n Figure 1. Number of new deaths from COVID-19 compared to the number of people who received at least one dose of vaccine for selected countries.\u00a0The graph shows data from the start of vaccination to May 3, 365, 2021. A) India (9.25% of the population vaccinated), B) Thailand (1.58% of the population vaccinated), C) Colombia (6 , 79% of the vaccinated population), D) Mongolia (31.65% of the vaccinated population), E) Israel (62.47% of the vaccinated population), F) Worldwide (7.81% of the vaccinated population) ).\u00a0Charts were constructed using data from Our World in Data (accessed May 4, 2021)\u00a0\u00a0https: \/\/ github.\u00a0com \/ owid \/ covid \u2013 19 \u2013 data \/ tree \/ master \/ public \/ data \/ vaccinations<\/a><\/p>\n Affiliations<\/strong><\/p>\n *<\/p>\n 1 Epidemi\u00f3logos Argentinos Metadisciplinarios.\u00a0Rep\u00fablica Argentina.
\n2 Baylor University Medical Center.\u00a0Dallas, Texas, United States.
\n3 Monestir de Sant Benet de Montserrat, Montserrat, Spain
\n4 INSERM U781 Necker-Enfants Malades Hospital, Paris Descartes-Sorbonne University City, Imagine Institute, Paris, France.
\n5 School of Natural Sciences.\u00a0Autonomous University of Quer\u00e9taro, Quer\u00e9taro, Mexico.
\n6 Retired professor of medical immunology.\u00a0Universidad de Guadalajara, Jalisco, Mexico.
\n7 Medicos por la Verdad Puerto Rico.\u00a0Ashford Medical Center.\u00a0San Juan, Puerto Rico.
\n8 Retired professor of clinical diagnostic process.\u00a0University of Murcia, Murcia, Spain
\n9Urologist Comarcal Hospital of Monforte, University of Santiago de Compostela, Spain.
\n10 Bi\u00f3logos por la Verdad, Spain.
\n11 Retired biologist.\u00a0University of Barcelona.\u00a0Specialized in microbiology.\u00a0Barcelona, \u200b\u200bSpain.
\n12 MICAEL Integrative Medicine Center (Medicina Integrativa Centro Antropos\u00f3fico Educando en Libertad).\u00a0Mendoza, Argentine Republic.
\n13 Medicos por la Verdad Argentina.\u00a0Rep\u00fablica Argentina.\u00a0\u00b4
\n14 M\u00e9dicos por la Verdad Uruguay.\u00a0Rep\u00fablica Oriental del Uruguay.
\n15 Medicos por la Libertad Chile.\u00a0Rep\u00fablica de Chile.
\n16 Doctor, orthopedist.\u00a0Rep\u00fablica de Chile.
\n17 Medicos por la Verdad Per\u00fa.\u00a0Rep\u00fablica del Per\u00fa.
\n18M\u00e9dicos por la Verdad Guatemala.\u00a0Rep\u00fablica de Guatemala.
\n19 Concepto Azul SA Ecuador.
\n20 Medicos por la Verdad Brasil.\u00a0Brazil.
\n21 Medicos por la Verdad Paraguay.
\n22 Medicines by Costa Rica.
\n23 Medicos por la Verdad Bolivia.
\n24 Medicos por la Verdad El Salvador.
\n* Correspondence: Karina Acevedo-Whitehouse,\u00a0\u00a0\u00a0karina.acevedo.whitehouse@uaq.mx<\/a><\/p>\n